Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Inspirna to Present Phase 1b RGX-202-01 Clinical Trial Data at the 2022 ESMO World Congress on Gastrointestinal Cancer


Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today data from the ongoing Phase 1b clinical trial studying RGX-202-01 in combination with FOLFIRI and bevacizumab (FOLFIRI/BEV) in second-line advanced colorectal cancer (CRC) at the 2022 European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer being held June 29 through July 2, 2022 in Barcelona, Spain.

"These clinical data continue to demonstrate the clear potential of RGX-202-01 to improve on the standard of care for patients with advanced or metastatic colorectal cancer, especially for those whose tumors harbor KRAS mutations," said Andrew Hendifar, M.D., Assistant Professor at Cedars-Sinai Medical Center and Principal Investigator on the study. "RGX-202-01 employs a novel mechanism by inhibiting the creatine transporter SLC6a8, which enables cells to generate ATP as well as other nucleotides by importing phospho-creatine (p-creatine). These results also show that KRAS mutant tumors are highly sensitive to the effects of SLC6a8 inhibition by RGX-202-01. The drug is also very well-tolerated, enabling a safe and effective combination therapy with FOLFIRI/BEV to provide further optionality for patients."

RGX-202-01 is an oral, potential first-in-class small molecule inhibitor of SLC6a8, a creatine transporter that drives colorectal cancer and certain other cancers' progression. It is currently being evaluated in a Phase 1b dose escalation and expansion study in combination with FOLFIRI/BEV in second-line, advanced or metastatic CRC. The primary endpoint of the study is to determine maximum tolerated dose (MTD), overall response rate (ORR), and treatment-emergent adverse events (TEAEs). In the dose escalation stage of the study, two dose levels of RGX-202-01 with FOLFIRI/BEV have been evaluated in patients with advanced or metastatic CRC who have progressed on available oxaliplatin based first line therapy. In the ongoing expansion stage, additional patients with CRC are being treated at the dose of 3000mg PO BID to provide further characterization of the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of the treatment.

Key findings to be presented at ESMO World Congress on Gastrointestinal Cancer:

The poster is available at the Annals of Oncology website and https://inspirna.com/presentations-publications/.

Poster Presentation Details

Title: Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC)

Date and time: July 1, 2022 at 10:30 ? 10:50am CEST and 4:30 ? 5pm CEST

Abstract Category: Clinical Colon Cancer

Abstract Subcategory: Metastatic Disease

Abstract ID: 291

About Inspirna

Inspirna, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancers of high unmet need. The company is pursuing two first-in-class small molecule drug candidates, RGX-202 and RGX-104. Inspirna's lead drug candidate RGX-202 is an orally-administered small molecule that targets the CKB/SLC6A8 pathway. This pathway becomes activated in the tumors of select patients with gastrointestinal cancers where it enables the generation of the energy molecule ATP in response to tumor hypoxia. RGX-202 is currently being tested in a Phase 1b clinical trial in combination with standard-of-care FOLFIRI and bevacizumab for the second line treatment of patients with advanced CRC. Inspirna is also developing a first in class small molecule that activates ApoE, RGX-104 (abequolixron), in high unmet medical need lung cancer settings and in advanced endometrial cancer in collaboration with Bristol-Myers Squibb.

Inspirna identifies novel cancer targets using its RNA-based target discovery platform, RNA-DRIVErtm, which was originally developed by Inspirna's scientific co-founders at The Rockefeller University and exclusively licensed to Inspirna. The Company brings together distinguished scientific founders, a seasoned board of directors, and a leadership team comprised of experienced drug developers. The Company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Sixty Degree Capital, K2 HealthVentures, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments, LLC, Exor Seeds, and the Partnership Fund for New York City. For more information, please visit www.inspirna.com.


These press releases may also interest you

at 21:05
BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound...

at 21:00
LG Electronics USA announced today the 2022 lineup of TONE Free® true wireless earbuds. The new models provide the ultimate sound experience with advanced audio technologies, a better-fitting design, and a host of useful, new features. The new TONE...

at 20:30
On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA"). Malignant glioma has...

at 20:10
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFN? in a...

at 20:00
NaoTrac, the CE-certified neurosurgical navigation robot, achieved approval from Taiwan's Food and Drug Administration (TFDA) in July 2022, and is planned for submission to the FDA (U.S. Food and Drug Administration) for clearance by the end of 2022....

at 20:00
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces the appointment of...



News published on 28 june 2022 at 08:10 and distributed by: